Teva trial data back higher dosage Copaxone The Phase III GALA trial found lower multiple sclerosis relapse rates when higher Copaxone doses are injected three times weekly rather than daily.
Heart valve implant co MitrAssist raises $1m MitrAssist has developed a minimally invasive approach to treating heart disorders in which the mitral valve does not close properly.